Quizartinib (AC220)

Name: Quizartinib (AC220)
Brand: Selleck Chemicals
SKU: S1526
Rating: 5 (94 reviews)

For research use only.

Catalog No.S1526

94 publications

CAS No. 950769-58-1

Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM in MV4-11 and RS4;11 cells, respectively, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Quizartinib (AC220) induces apoptosis of tumor cells. Phase 3.

Selleck's Quizartinib (AC220) has been cited by 94 publications

Cancer Cell, 2018, 34(2):315-330

PubMed: 30033091 ( click the link to review the publication )

Nat Med, 2017, 23(1):69-78

PubMed: 27941792 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00507-4

PubMed: 34289383 ( click the link to review the publication )

Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-20-3458

PubMed: 34103301 ( click the link to review the publication )

Autophagy, 2021, 1-10

PubMed: 33446043 ( click the link to review the publication )

Leukemia, 2021, 10.1038/s41375-021-01308-z

PubMed: 34127794 ( click the link to review the publication )

Cancer Res, 2021, canres.3761.2020

PubMed: 34215619 ( click the link to review the publication )

Blood Cancer J, 2021, 11(3):57

PubMed: 33714981 ( click the link to review the publication )

Protein Cell, 2021, 10.1007/s13238-021-00858-3

PubMed: 34291435 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):121

PubMed: 34035227 ( click the link to review the publication )

Front Immunol, 2021, 12:699128

PubMed: 34249005 ( click the link to review the publication )

Cancer Discov, 2021, candisc.0738.2020

PubMed: 33436370 ( click the link to review the publication )

Mol Cancer Ther, 2021, 20(4):676-690

PubMed: 33568357 ( click the link to review the publication )

mSphere, 2021, 6(1)e00986-20

PubMed: 33408225 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Oncol Lett, 2021, 21(5):397

PubMed: 33777220 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Thorac Cancer, 2021, 10.1111/1759-7714.13849

PubMed: 33566442 ( click the link to review the publication )

Cell Rep, 2020, 33(1):108221

PubMed: 33027668 ( click the link to review the publication )

Haematologica, 2020, 15 pii: haematol 2019 244020

PubMed: 32414851 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 10.1074/mcp.RA119.001504

PubMed: 32102969 ( click the link to review the publication )

Eur J Med Chem, 2020, 193:112232

PubMed: 32199135 ( click the link to review the publication )

J Cell Mol Med, 2020, 25

PubMed: 32450611 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(3):2308-2318

PubMed: 31881122 ( click the link to review the publication )
Sci Rep, 2020, 10(1):16187

PubMed: 32999332 ( click the link to review the publication )

Sci Rep, 2020, 10(1):1906

PubMed: 32024878 ( click the link to review the publication )

Transl Oncol, 2020, 1;13(4):100766

PubMed: 32247263 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Pharmacol Res, 2020, 151:104556

PubMed: 31778791 ( click the link to review the publication )

FEBS Open Bio, 2020, 10.1002/2211-5463.12827

PubMed: 32128992 ( click the link to review the publication )

Sci Transl Med, 2019,

PubMed: 31484791 ( click the link to review the publication )

Autophagy, 2019, 15(9):1558-1571

PubMed: 30821613 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31554189 ( click the link to review the publication )

Theriogenology, 2019, 126:145-152

PubMed: 30553232 ( click the link to review the publication )

Cell Rep, 2019, 26(11):2916-2928.e13

PubMed: 30865883 ( click the link to review the publication )

Hemasphere, 2019, 3(2):e182

PubMed: 31723821 ( click the link to review the publication )

FEBS Lett, 2019, 593(16):2162-2176

PubMed: 31135968 ( click the link to review the publication )

Oncotarget, 2019, 10(58):6111-6123

PubMed: 31692922 ( click the link to review the publication )

Blood, 2018, 25;131(4):426-438

PubMed: 29187377 ( click the link to review the publication )

Blood, 2018, 132(1):67-77.

PubMed: 29784639 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(7):1716-1726

PubMed: 29330206 ( click the link to review the publication )

Leukemia, 2018, 32(2):313-322

PubMed: 28895560 ( click the link to review the publication )

Haematologica, 2018, haematol.2018.189399

PubMed: 29748445 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(10):2417-2429

PubMed: 29463558 ( click the link to review the publication )

Oncogene, 2018, 37(6):787-797

PubMed: 29059168 ( click the link to review the publication )
mBio, 2018, 9(2)e00682-18

PubMed: 29691342 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):138

PubMed: 29374185 ( click the link to review the publication )

Neoplasia, 2018, 20(1):1-11

PubMed: 29172076 ( click the link to review the publication )

Nephrol Dial Transplant, 2018, 10.1093/ndt/gfy385

PubMed: 30590794 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190682

PubMed: 29298347 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0196805

PubMed: 29723246 ( click the link to review the publication )

Exp Hematol, 2018, 58:52-58

PubMed: 28947392 ( click the link to review the publication )

J Ophthalmol, 2018, 2018:2518568

PubMed: 29854425 ( click the link to review the publication )

Oncotarget, 2018, 9(76):34240-34258

PubMed: 30344940 ( click the link to review the publication )

Leukemia, 2018, 32(11):2374-2387

PubMed: 29743719 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16917-16931

PubMed: 29682194 ( click the link to review the publication )

Blood, 2017, 130(1):48-58

PubMed: 28490572 ( click the link to review the publication )

Leukemia, 2017, 31(11):2336-2346

PubMed: 28280274 ( click the link to review the publication )

Cancer Res, 2017, 77(7):1697-1708

PubMed: 28108507 ( click the link to review the publication )

Leuk Lymphoma, 2017, 10.1080/10428194.2017.1289522

PubMed: 28276286 ( click the link to review the publication )

Blood Adv, 2017, 1(20):1635-1644

PubMed: 29296810 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52026-52044

PubMed: 28881711 ( click the link to review the publication )

Blood, 2016, 127(23):2890-902

PubMed: 27099147 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1528-37

PubMed: 26822154 ( click the link to review the publication )

Cancer Res, 2016, 76(5):1214-24

PubMed: 26833125 ( click the link to review the publication )

Sci Rep, 2016, 6:28032

PubMed: 27346558 ( click the link to review the publication )

Ann Hematol, 2016, 95(5):783-91

PubMed: 26891877 ( click the link to review the publication )

PLoS One, 2016, 11(7):e0158290

PubMed: 27387666 ( click the link to review the publication )

Int J Hematol, 2016, 103(1):95-106

PubMed: 26590920 ( click the link to review the publication )
Oncotarget, 2016, 7(31):49786-49799

PubMed: 27391351 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13886-901

PubMed: 26883104 ( click the link to review the publication )

Leukemia, 2015, 29(12):2382-9

PubMed: 26172401 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

Sci Adv, 2015, 1(8):e1500221

PubMed: 26601252 ( click the link to review the publication )

Oncotarget, 2015, 6(35):38061-78

PubMed: 26515730 ( click the link to review the publication )

Blood, 2014, 123(18):2826-37

PubMed: 24668492 ( click the link to review the publication )

Blood, 2014, 123(5):734-42

PubMed: 24282218 ( click the link to review the publication )

Nat Commun, 2014, 5:3672

PubMed: 24739485 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Leukemia, 2014, 28(2):293-301

PubMed: 23748345 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Genes Dev, 2014, 28(11):1179-90

PubMed: 24888589 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1320661111

PubMed: 24623852 ( click the link to review the publication )

Cancer Discov, 2014, 4(2):200-15

PubMed: 24362263 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

J Biol Chem, 2014, 289(45):31053-65

PubMed: 25237195 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74653

PubMed: 24040307 ( click the link to review the publication )

PLoS One, 2013, 8(8): e71266

PubMed: 23967177 ( click the link to review the publication )

Leuk Res, 2013, 37(11):1557-64

PubMed: 23998902 ( click the link to review the publication )

Br J Pharmacol, 2012, 166(3):858-76

PubMed: 22250956 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Target Protein Ligand Inhibitors

Biological Activity

Description

Features

The most potent cellular FLT3-ITD inhibitor.

Targets

FLT3 (ITD) ^[1] (MV4-11 cells)	FLT3 (WT) ^[1] (RS4;11 cells)
1.1 nM	4.2 nM

In vitro

AC220, a unique, potent and selective inhibitor of FLT3, has high affinity for FLT3 with a K_d value of 1.6 nM. AC220 inhibits the autophosphorylation of FLT3 in the human leukemia cell lines MV4-11 which harbor a homozygous FLT3-ITD mutation and is FLT3 dependent, and RS4;11 which expresses wild-type FLT3 with IC50 values of 1.1 nM and 4.2 nM, respectively. AC220 is the most potent cellular FLT3-ITD inhibitor, leading to the most significant inhibition of MV4-11 cell proliferation with IC50 of 0.56 nM compared to all other FLT3 inhibitors whose IC50 values range from 0.87 nM to 64 nM. AC220 has no inhibitory activity against the proliferation of A375 cells which harbor an activating mutation in BRAF and are not FLT3 dependent, indicating a large window between FLT3 inhibition and general cytotoxic effects. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HL60/VCR	NFHUdXZHfW6ldHnvckBCe3OjeR?=	M2rSV\|AvOS1zMDFOwG0>	M2DEWVMxKG2rbh?=	NFjWNlJmdmijbnPld{B2eHSja3Wgc4Yhe3Wkc4TyZZRmeyCxZjDBRmNIOiCjbnSgRWJESjFiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ?	MlG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkexO\|coRjJ\|OU[3NVc4RC:jPh?=
K562/ABCB1	NID6NHZHfW6ldHnvckBCe3OjeR?=	M1PHPFAvOS1zMDFOwG0>	Mk\rN\|AhdWmw	NV\QTJBY\W6qYX7j[ZMhfXC2YXvlJI9nKHO3YoP0doF1\XNib3[gRWJETzJiYX7kJGFDS0JzIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{	Ml7EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkexO\|coRjJ\|OU[3NVc4RC:jPh?=
8226/MR20	NH3pZVJHfW6ldHnvckBCe3OjeR?=	MoSxNE4yNTFyIN88US=>	NGT6O3o{OCCvaX6=	MUDlcohidmOnczD1dJRic2Vib3[gd5Vje3S{YYTld{Bw\iCDQlPHNkBidmRiQVLDRlEhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI>	NE\MNVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2O\|E4Pyd-MkO5OlcyPzd:L3G+
K562/ABCG2	MnP0SpVv[3Srb36gRZN{[Xl?	M2HXUlAvOS1zMDFOwG0>	MUKzNEBucW5?	M3LVOIVvcGGwY3XzJJVxfGGtZTDv[kB{fWK\|dILheIV{KG:oIFHCR2czKGGwZDDBRmNDOSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>?	NFGydYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2O\|E4Pyd-MkO5OlcyPzd:L3G+
MCF-7 FLV1000	MlPPT4lv[XOnIFHzd4F6	MVqw5qCUOzBiwsXN	NXjnZ3JQPSCvaX6=	MoTF[IVkemWjc3XzJHsyOjWLXT3JRWFRKHCqb4TvcIFj\Wyrbnegc4YhSUKFQkGgZZQhUUN3MDDv[kA{NjNizszN	MkHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkexO\|coRjJ\|OU[3NVc4RC:jPh?=
MCF-7 FLV1000	NFPOTJNMcW6jc3WgRZN{[Xl?	Mli1NQKBmzNyINM1US=>	Mn;kOUBucW5?	M13zNoRm[3KnYYPld{BcOTJ3SW2tTWFCWCCyaH;0c4xi[mWuaX7nJI9nKEGEQ1KyJIF1KEmFNUCgc4YhOC5yNzFOwG0>	NIXVU4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2O\|E4Pyd-MkO5OlcyPzd:L3G+
K562/ABCG2	Mn7SR4VtdCCYaXHibYxqfHliQYPzZZl{	MlH6NE4yNzBwNT:xJOK2VQ>?	NI\CV\|c6PiCq	Ml7ad4Vve2m2aYrld{BMPTZ{L1HCR2czKGOnbHzzJJRwKG2rdH;4ZY51em:wZTD0c5BwfGWlYX9CpC=>	NXT1T\|k6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlcyPzdpPkKzPVY4OTd5PD;hQi=>
8226/MR20	NGD2XmRE\WyuIG\pZYJqdGm2eTDBd5NigXN?	M2nFZlAvOSEEtV2=	Ml\5PVYhcA>?	MYfz[Y5{cXSrenXzJGs2PjJxQVLDS\|Ih[2WubIOgeI8hdWm2b4jhcpRzd26nIITvdI91\WOjbtMg	MlLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkexO\|coRjJ\|OU[3NVc4RC:jPh?=
HMC1.1	MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXvJVHJoUUN3ME2xOEBvVQ>?	NFnFSZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
HMC1.2	M1rWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3TlT2lEPTB;MUeyO{BvVQ>?	NYDRTJVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
p815	M17STGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV7JR\|UxRTR2NTDuUS=>	NVHXXJJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
Kasumi-1	NYjXTpE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYDJR\|UxRTN4IH7N	M17MdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
M-07e + SCF	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYTJR\|UxRTd5IH7N	MmKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
EOL-1	M3\PNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYPheGZLUUN3ME2xJI5O	MlXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
MV4;11	M4\2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoTGTWM2ODxiMTDuUS=>	NEPSWGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
MOLM14	MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWPGcGZjUUN3MEygNUBvVQ>?	Ml7XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
Pat.221	NX\6U3hWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlnqTWM2OD14N{Wgcm0>	NWPOdmhRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
Pat.279	Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NH;ITlVKSzVyPUO0N\|Qhdk1?	NWPaWmZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
Pat.299	NInSeZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUG3[2VwUUN3ME23NlQ5KG6P	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
Pat.305	MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYP0bndmUUN3ME23NFc6KG6P	M1POXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
Pat.375	NV7sUm1YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIfmOY5KSzVyPUWwN{BvVQ>?	M1XwbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
Pat.379	NW[3Nmh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV7abYJZUUN3ME24NFYhdk1?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
Pat.368	NFLKdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWCxPW86UUN3ME2yO\|AxKG6P	NFy0TVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
Pat.601	NYHQVIpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFm5UlZKSzVyPUGxOVMhdk1?	MmHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
HMC1.1	M1rkXGFxd3C2b4Ppd{BCe3OjeR?=			NYPJdFR[UUN3ME2zNUBvVQ>?	M{jGcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
p815	Mo\jRZBweHSxc3nzJGF{e2G7			MXvJR\|UxRTN2MTDuUS=>	M2P6UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
Kasumi-1	NUCze3ZiSXCxcITvd4l{KEG\|c3H5			NHewZppKSzVyPU[3JI5O	M1rSOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
M-07e + SCF	M3zU[mFxd3C2b4Ppd{BCe3OjeR?=			MXTJR\|UxRTd6IH7N	NV3ie4pkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
EOL-1	MmLNRZBweHSxc3nzJGF{e2G7			NHm1NGRKSzVyPDCxJI5O	NUf4[XF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
MV4;11	M33T[GFxd3C2b4Ppd{BCe3OjeR?=			MlnvTWM2OD1{IH7N	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
MOLM14	NX3GTlE1SXCxcITvd4l{KEG\|c3H5			NIXDeZJKSzVyPUOgcm0>	NGjQ[2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
GIST822	NFPKTIZCeG:ydH;zbZMhSXO\|YYm=			MlK3TWM2OD1zMEmgcm0>	MlLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
Pat.368	M1;KNGFxd3C2b4Ppd{BCe3OjeR?=			MlzITWM2OD1{OUm4JI5O	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
Pat.601	NE\6PZZCeG:ydH;zbZMhSXO\|YYm=			MWLJR\|UxRTh5NjDuUS=>	M3TaT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
MV4-11	NYTuZodqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIrkcJg4OiCq	MoHjTWM2OD1yLkOgcm0>	M3n3c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEGyPVMyLz5{M{SxNlk{OTxxYU6=
MOLM-14	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3jhSlczKGh?	MXfJR\|UxRTBwMTDuUS=>	M2nMRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEGyPVMyLz5{M{SxNlk{OTxxYU6=
SEM-K2	M3PEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWj1b49HPzJiaB?=	MY\JR\|UxRTBwNDDuUS=>	M4PsNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEGyPVMyLz5{M{SxNlk{OTxxYU6=
RS4;11	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mk\DO\|IhcA>?	NES2OVRKSzVyPkGwMFAxOCCwTR?=	NGrvd3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxNlk{OSd-MkO0NVI6OzF:L3G+
THP-1	NH72NnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3WyWFczKGh?	M{HZcmlEPTB-MUCsNFAxKG6P	NH;ZOpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxNlk{OSd-MkO0NVI6OzF:L3G+
MV4-11	MmPnRZBweHSxc3nzJGF{e2G7		NHHtcm05NzJ2IHi=	NVS0VlRScW6mdXPld{B{cWewaX\pZ4FvfCCjbnSg[I9{\S2mZYDlcoRmdnRiUFHSVEBkdGWjdnHn[UBidmRiYXPjeY12dGG2aX;uJI9nKHO3Yj2yUkBFVkF?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzMkmzNUc,OjN2MUK5N\|E9N2F-
MOLM-14	MkjIRZBweHSxc3nzJGF{e2G7		M3uzblgwOjRiaB?=	MWTpcoR2[2W\|IIPp[45q\mmlYX70JIFv\CCmb4PlMYRmeGWwZHXueEBRSVKSIHPs[YF3[WenIHHu[EBi[2O3bYXsZZRqd25ib3[gd5VjNTKQIFTORS=>	NIjT[VQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxNlk{OSd-MkO0NVI6OzF:L3G+
SEM-K2	MX3BdI9xfG:\|aYOgRZN{[Xl?		MnOyPE8zPCCq	MknXbY5lfWOnczDzbYdvcW[rY3HueEBidmRiZH;z[U1l\XCnbnTlcpQhWEGUUDDjcIVifmGpZTDhcoQh[WOldX31cIF1cW:wIH;mJJN2[i1{TjDEUmE>	M1;qOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEGyPVMyLz5{M{SxNlk{OTxxYU6=
AML	M135UmN6fG:2b4jpZ4l1gSCjc4PhfS=>			NXS5NWdRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSU2OIHPlcIx{KGm\|b3zheIVlKG[{b32gdoVt[XC\|ZXSgZYN2fGVibYnlcI9q\CCuZYXr[Y1q[SCyYYTp[Y51KGijcnLvdolv\yCITGSzJGlVTCCvdYTheIlwdiCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAxODNizszNMi=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ3NESwPEc,OTl4NUS0NFg9N2F-
MV4-11	M4LISmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NFnIXI04OiCqcoO=	M1PGPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1XPC1zMTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[2WubDD0bZRmei2kbIXlJIF{e2G7LDDJR\|UxKD1iMD6wNFA2PiEQvF2u	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ3NESwPEc,OTl4NUS0NFg9N2F-
blast cells	MoLVSpVv[3Srb36gZZN{[Xl?		NGfUcIkzKGi{cx?=	M3e2WGlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iYnzhd5Qh[2WubIOgZYZ1\XJiMjDodpMh[nliZXzlZ5Rzd2OqZX3pcJVucW6nc3PlcoNmNCCLQ{WwJF0hOC5yMEC4JO69VS5?	MkHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4NUS0NFgoRjF7NkW0OFA5RC:jPh?=
RS4-11	MXjGeY5kfGmxbjDhd5NigQ>?		NV;SVXdIOiCqcoO=	M{jydGlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iUmO0MVEyKGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHXs[YN1em:laHXtbYx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODBzMTFOwG0v	NV7RNZI3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2OVQ1ODhpPkG5OlU1PDB6PD;hQi=>
AML	NH3V[ZpHfW6ldHnvckBie3OjeR?=			MV;Jcohq[mm2aX;uJI9nKE[OVEOgZZV1d3Cqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBCVUxiY3XscJMhcXOxbHH0[YQh\nKxbTDy[YxieHOnZDDhZ5V1\SCveXXsc4llKGyndXvlcYliKHCjdHnlcpQh[nliV3XzeIVzdiCkbH;0eIlv\yxiSVO1NEA:KDBwMECyJO69VS5?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ3NESwPEc,OTl4NUS0NFg9N2F-
RS4-11	NYK0eHRGTnWwY4Tpc44h[XO\|YYm=		MUCyJIhzew>?	NU\vZ4hQUW6qaXLpeIlwdiCxZjDGUHQ{KGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iUmO0MVEyKGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHXs[YN1em:laHXtbYx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODB2MjFOwG0v	NXnNcnAyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2OVQ1ODhpPkG5OlU1PDB6PD;hQi=>
MV4-11	NXLaWW9tSW62aYT1cY9zKGG\|c3H5	NH;0TnIyOCCvZz;r[y=>	NYWzcnZxPjBiZHH5dy=>	M3z4W2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3WOE0yOSClZXzsd{B5\W6xZ4Lh[pRm\CCvb4Xz[UBud2SnbDDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIT1cY9zKHKnZ4Lve5RpKGG2IHH0JFExKG2pL3vnMEBxdyB4MDDkZZl{KHCxc4SgeJJm[XSvZX70	NYruXI9ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2OVQ1ODhpPkG5OlU1PDB6PD;hQi=>
MV4-11	MYHBcpRqfHWvb4KgZZN{[Xl?	M4XheVEhdWdxa3ev[IF6	M3;nOVMxKGSjeYO=	NFn4e5NCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMhgGWwb3fyZYZ1\WRibX;1d4Uh[m:wZTDtZZJzd3diZX7ndoFnfG2nboSgcY9l\WxiYYPz[ZN{\WRiYYOgbY5kemWjc3WgcY92e2VibHnm[UB{eGGwIHH0JFEhdWdxa3ev[IF6NCCybzDmc5IhOzBiZHH5d{Bu\WG\|dYLl[EBwdiCmYYmgO\|cheG:\|dDDkc5Nm	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ3NESwPEc,OTl4NUS0NFg9N2F-
MV4-11	MornRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NH;QTIo4OiCqcoO=	Mn3CRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHPlcIwhfGm2ZYKtZox2\SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuNFAxPTZizszNMi=>	NGDpTmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe1OFE6QSd-MUm3OVQyQTl:L3G+
HEK293	MU\GeY5kfGmxbjDhd5NigQ>?			MlHTRolv\GmwZzDh[oZqdmm2eTD0c{BHVFR\|IHPheIFtgXSrYzDkc41icW5iZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCkeTDjc41x\XSrdHn2[UBjcW6maX7nJIF{e2G7LDDL[EA:KDBwMECxOkDPxE1w	Mo\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NUSxPVkoRjF7N{W0NVk6RC:jPh?=
MV4-11	MX\BcpRqfHWvb4KgZZN{[Xl?	MYSxJI1oN2up	NU\UfVRiOjhiZHH5dy=>	NEDufZNCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMhgGWwb3fyZYZ1\WRiaX6gZZRpgW2rYzDueYRmKG2xdYPlJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JiZ4Lve5RpKGG2IEGgcYcwc2duIIDvJHFFKG[xcjCyPEBl[Xm\|IH3lZZN2emWmIHT1dolv\yCmb4PpcocheGW{aX;k	NXzUbYxFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OVQyQTlpPkG5O\|U1OTl7PD;hQi=>
MV4-11	Mo\5RY51cXS3bX;yJIF{e2G7	NVLCRpNNOyCvZz;r[y=>	NVznSGE3OjhiZHH5dy=>	NWC2eII4SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KHinbn;ndoFnfGWmIHnuJIF1cHmvaXOgcpVl\SCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigdoVoemW\|c3nvckBifCB\|IH3nM4toNCCybzDRSEBnd3JiMkig[IF6eyCvZXHzeZJm\CCjZoTldkBld3OrbnegdIVzcW:m	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd3NEG5PUc,OTl5NUSxPVk9N2F-
MV4-11	MUPBcpRqfHWvb4KgZZN{[Xl?	MUixNEBu\y:tZx?=	MYmyPEBl[Xm\|	MWnBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgfIVvd2e{YX\0[YQhcW5iYYTofY1q[yCwdXTlJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCC{ZXfy[ZN{cW:wIHH0JFExKG2pL3vnMEBxdyCTRDDmc5IhOjhiZHH5d{Bu\WG\|dYLl[EBi\nSncjDkc5NqdmdicHXybY9l	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd3NEG5PUc,OTl5NUSxPVk9N2F-
MV4-11	MX\BcpRqfHWvb4KgZZN{[Xl?	M2rPTlMhdWdxa3e=	NGr2cWYzQCCmYYnz	NVnVd2FUSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KHinbn;ndoFnfGWmIHnuJIF1cHmvaXOgcpVl\SCvb4Xz[UBie3Onc4Pl[EBieyC\|dYDwdoV{e2mxbjDv[kB1fW2xcjD2c4x2dWViYYSgN{Bu\y:tZzygdI8hWURiZn;yJFI5KGSjeYOgcYVie3W{ZXSgZYZ1\XJiZH;zbY5oKHCncnnv[C=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd3NEG5PUc,OTl5NUSxPVk9N2F-
MV4-11	NGjDdGJCdnSrdIXtc5Ih[XO\|YYm=	NU\PSXQ1OTBibXevb4c>	MmXoNlgh\GG7cx?=	MUDBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgfIVvd2e{YX\0[YQhcW5iYYTofY1q[yCwdXTlJI1wfXOnIHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIIT1cY9zKH[xbIXt[UBifCBzMDDt[{9s\yxicH:gVWQh\m:{IEK4JIRigXNibXXhd5Vz\WRiYX\0[ZIh\G:\|aX7nJJBmemmxZB?=	MkKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NUSxPVkoRjF7N{W0NVk6RC:jPh?=
MV4-11	MlXSRY51cXS3bX;yJIF{e2G7	M3nsfVExKG2pL3vn	Ml\CNlgh\GG7cx?=	NWfCdG5DSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KHinbn;ndoFnfGWmIHnuJIF1cHmvaXOgcpVl\SCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHfyc5d1cCCjdDCxNEBu\y:tZzygdI8hWURiZn;yJFI5KGSjeYOgcYVie3W{ZXSgZYZ1\XJiM{Kg[IF6eyCyb4P0[I9{\Q>?	NE\COG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe1OFE6QSd-MUm3OVQyQTl:L3G+
MOLM13	M17OVmFvfGmycn;sbYZmemG2aY\lJIF{e2G7			NH2xUW5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yOyClZXzsd{BmgHC{ZYPzbY5oKE[OVEOtTXRFKG23dHHueEwhT0l3MDC9JFAvODB2IN88UU4>	MnToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5Mk[5N\|EoRjJ{N{K2PVMyRC:jPh?=
MV411	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoHnOFghcHK\|	MkHBS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUXY1OTFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHhVXCCjc4PhfUwhT0l3MDC9JFMvOzFizszNMi=>	NV\0cHNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFgxPzlpPkK1NVA5ODd7PD;hQi=>
THP1	NETwN4pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M13QZ\|Q5KGi{cx?=	M3zXNWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHRJWDFiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHhVXCCjc4PhfUwhT0l3MDC9JFUvPTd2IN88UU4>	NVrJVWVRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFgxPzlpPkK1NVA5ODd7PD;hQi=>
HL60	NX;zVGNET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnrPOFghcHK\|	NF72coJIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJVDZyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBZXFRiYYPzZZktKEeLNUCgQUA5NjBzNDFOwG0v	NY\WdVNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFgxPzlpPkK1NVA5ODd7PD;hQi=>
32D	MlziSpVv[3Srb36gZZN{[Xl?		NWPEW\|ZNPzJiaILz	M3fBXmlvcGmkaYTpc44hd2ZiaIXtZY4hTkyWMzDJWGQhdXW2YX70JIV5eHKnc4Pl[EBqdiCvb4Xz[UA{OkRiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyIE2gNE4xODByMTFOwG0v	NH7rcoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
MV4-11	NEDDSmhHfW6ldHnvckBie3OjeR?=		NXHWbXprPzJiaILz	NEjOVYdKdmirYnn0bY9vKG:oIF\MWFMhUVSGIHjvcY97gWexdYOgcZV1[W62IHnuJIh2dWGwIF3WOE0yOSClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGdKPTBiPTCwMlAxOyEQvF2u	NIrDemQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
MOLM-13	NY\3SpVITnWwY4Tpc44h[XO\|YYm=		MYS3NkBpenN?	MUfJcohq[mm2aX;uJI9nKE[OVEOgTXRFKGindHXyc5p6\2:3czDteZRidnRiaX6gbJVu[W5iTV;MUU0yOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGdKPTBiPTCwMlAxPCEQvF2u	NGXDVnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
32D	NYmze4pDTnWwY4Tpc44h[XO\|YYm=		Ml;uO\|IhcHK\|	NIT0OnVKdmirYnn0bY9vKG:oIHTyeYchemW\|aYP0ZY51KGi3bXHuJGZNXDNiSWTEJGQ5OzW\IH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViM{LEJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiR1m1NEA:KDBwMEG2JO69VS5?	Ml7FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOEGwNlMoRjJ4MEixNFI{RC:jPh?=
32D	MlvtSpVv[3Srb36gZZN{[Xl?		NHXDbGs4OiCqcoO=	MmfRTY5pcWKrdHnvckBw\iCmcoXnJJJme2m\|dHHueEBpfW2jbjDGUHQ{KEmWRDDEPFM2XiCvdYThcpQh\XiycnXzd4VlKGmwIH3veZNmKDN{RDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEeLNUCgQUAxNjB{NzFOwG0v	NFHIZ2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
Sf9	NF;J[ZFHfW6ldHnvckBie3OjeR?=		NX23[oFZPCCqcoO=	M3LJ[WlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFfTWE11[WepZXSgSmxVOyCtaX7hd4Uh\G:vYXnuJEh[PTZ5IITvJHM6QTNrIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKGmwc3XjeEBU\jliY3XscJMhfXOrbnegTIVzOiCyZYD0bYRmKGG\|IIP1ZpN1emG2ZTDh[pRmeiB2IHjyd{BjgSCNaX7hd4UuT2yxIHHzd4F6NCCLQ{WwJF0hOC5yNkmg{txONg>?	NHTLeHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
32D	MWrGeY5kfGmxbjDhd5NigQ>?		MUi3NkBpenN?	NHzOSo9KdmirYnn0bY9vKG:oIHTyeYchemW\|aYP0ZY51KGi3bXHuJGZNXDNiSWTEJGQ5OzWIIH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViM{LEJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiR1m1NEA:KDBwMUWg{txONg>?	M2PEPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEixNFI{Lz5{NkC4NVAzOzxxYU6=
32D	MV7GeY5kfGmxbjDhd5NigQ>?		NHTMeHY4OiCqcoO=	NUPrbZpPUW6qaXLpeIlwdiCxZjDkdpVoKHKnc3nzeIFvfCCqdX3hckBHVFR\|IFnUSEBHPjlzTDDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIEOySEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVAhRSByLkKyJO69VS5?	MlPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOEGwNlMoRjJ4MEixNFI{RC:jPh?=
Sf9	M3\MVmZ2dmO2aX;uJIF{e2G7		MX[xNlAhdWmwcx?=	M1X5PWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgS3NVNXSjZ3fl[EBXTUeIUkKgb4lv[XOnIHTvcYFqdiBqVke4PUB1dyCYMUO1OkkhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoOTDj[YxteyC3c3nu[{Bxd2y7R3z1OFpVgXJicHXweIll\SCjczDzeYJ{fHKjdHWgZYZ1\XJiMUKwJI1qdnNiYomgT4lv[XOnLVfsc{Bie3OjeTygTWM2OCB;IECuOFMh\|ryPLh?=	M{DJW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEixNFI{Lz5{NkC4NVAzOzxxYU6=
RS4:11	NYLMSY1MTnWwY4Tpc44h[XO\|YYm=		NITpfXU4OiCqcoO=	M4nad2lvcGmkaYTpc44hd2Zid3ns[EB1gXCnIHjvcY97gWexdYOgSmxVOyCrbjDoeY1idiCUU{S6NVEh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDHTVUxKD1iMj6yJO69VS5?	NVHVNW1TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFExOjNpPkK2NFgyODJ\|PD;hQi=>
MV4-11	M3jwOWFvfGm2dX3vdkBie3OjeR?=	NUm3[5F{OTBibXevb4c>	NYXaWHU6PDhiZHH5dy=>	M3i0ZmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3WOE0yOSClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueYRmKG2xdYPlJIF{e2W\|c3XkJIF{KHS3bX;yJJJm\3Knc4Ppc44h[XRiMUCgcYcwc2duIIDvJJFlKGGmbXnubZN1\XKnZDDvckBl[XliMTD0c{A2KG2nYYP1doVlKGS3cnnu[{A1QCCmYYnzJJBwe3RibHHzeEBld3On	NUfTSHZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFExOjNpPkK2NFgyODJ\|PD;hQi=>
MV4-11	M2[0VmFvfGm2dX3vdkBie3OjeR?=	MVqxNEBu\y:tZx?=	NIOzV5o1QCCmYYnz	NVXMXFhLSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KHinbn;ndoFnfGWmIHnuJI52\GVibX;1d4Uh[XO\|ZYPz[YQh[XNidIXtc5IhemWpcnXzd4lwdiCjdDCxNEBu\y:tZzygdI8heWRiYXTtbY5qe3SncnXkJI9vKGSjeTC4JJRwKDF{IH3lZZN2emWmIHT1dolv\yB2ODDkZZl{KHCxc4SgcIF{fCCmb4Pl	Mkn5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOEGwNlMoRjJ4MEixNFI{RC:jPh?=
MV4-11	M3zXemN6fG:2b4jpZ4l1gSCjc4PhfS=>		M4DMclczKGi{cx?=	MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xODB4ODFOwG0v	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF2MkOxO{c,OjZzNEKzNVc9N2F-
Sf21	MUfGeY5kfGmxbjDhd5NigQ>?		MYSxOUBucW6\|	NF\YRYlKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIF\MWFMh\XiycnXzd4VlKGmwIHnud4VkfCCVZkKxJINmdGy\|IIDy[Ylv[3WkYYTl[EBnd3JiMUWgcYlveyCob3zsc5dm\CCkeTDwc4x6MEeudUrUfZIqKHO3YoP0doF1\SCjZHTpeIlwdiCob4KgN\|AhdWmwczDpckBxemW\|ZX7j[UBw\iCdZ3HtcYEuOzKSXVHUVEBjgSCWUj3GVmVVKGG\|c3H5MEBKSzVyIE2gNE4xOjZyODFOwG0v	NV\CXGJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFc5PjBpPkK3NVg4QDZyPD;hQi=>
MV4-11	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYi0PEBpenN?	Ml33S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUXY1NTFzIHPlcIx{KGW6cILld5NqdmdiRlzUN{1KXERiYX\0[ZIhPDhiaILzJIJ6KFiWVDDhd5NigSxiR1m1NEA:KDFwMUCzJO69VS5?	NFTqWJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G4O\|g3OCd-MkexPFc5PjB:L3G+
HL60	Mke3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mn3oOFghcHK\|	MVPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIUFYxKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKE[OVD2zJIFnfGW{IES4JIhzeyCkeTDYWHQh[XO\|YYmsJGdKPTBiPTCxMlQ5QCEQvF2u	M1vERlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUi3PFYxLz5{N{G4O\|g3ODxxYU6=
THP1	NGK3ZWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mlj0OFghcHK\|	MlTvS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWGhROSClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCITGStN{Bi\nSncjC0PEBpenNiYomgXHRVKGG\|c3H5MEBIUTVyIE2gNk4yOjVizszNMi=>	MnLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzOEe4OlAoRjJ5MUi3PFYxRC:jPh?=
K562	MorWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXLDRYNtPDhiaILz	M4[4PWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGs2PjJiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHhVXCCjc4PhfUwhT0l3MDC9JFIvPjN6IN88UU4>	NX;PVJYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFc5PjBpPkK3NVg4QDZyPD;hQi=>
Sf21	NUi2TmhTTnWwY4Tpc44h[XO\|YYm=		NFLLWpMyOCCvaX7z	NVTqcplvUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGdUXC22YXfn[YQhemWlb33ibY5idnRiaIXtZY4hf2muZD30fZBmKE[OVEOgLFU3PCC2bzDlcoQhemW\|aXT1[ZMqKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EB{\jJzIHPlcIx{KHW\|aX7nJGFjdHSrZHWgZZMhe3Wkc4TyZZRmKGmwIIDy[ZNmdmOnIH;mJHto[W2vYUOzVH1CXFBiYX\0[ZIhOTBibXnud{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nJI1mfGixZDygTWM2OCB;IECuNFI2PSEQvF2u	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB2M{e5OEc,OjhyNEO3PVQ9N2F-
Sf21	NVvsU4FTTnWwY4Tpc44h[XO\|YYm=		NXzhbIFGOTBibXnudy=>	MVTJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiR2PUMZRi\2enZDDy[YNwdWKrbnHueEBpfW2jbjD3bYxlNXS7cHWgSmxVOyBqNU[0JJRwKGWwZDDy[ZNq\HWnczmgSFg{PVlibYX0ZY51KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EB{\jJzIHPlcIx{KHW\|aX7nJGFjdHSrZHWgZZMhe3Wkc4TyZZRmKGmwIIDy[ZNmdmOnIH;mJHto[W2vYUOzVH1CXFBiYX\0[ZIhOTBibXnud{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nJI1mfGixZDygTWM2OCB;IECuNlM2PSEQvF2u	NIPjeXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEC0N\|c6PCd-MkiwOFM4QTR:L3G+
MV4-11	MnS5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MYLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNWlQuOTFiY3XscJMhcGG{Yn;ybY5oKE[OVEOtTXRFKG23dHHueEBjgSC[VGSgZZN{[XluIFfJOVAhRSBzLkGwN{DPxE1w	NEXYXXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEC0N\|c6PCd-MkiwOFM4QTR:L3G+
THP1	NH7WfYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NHy2R3JIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBVUFBzIHPlcIx{KGijcnLvdolv\yC5aXzkMZR6eGViRlzUN{BjgSC[VGSgZZN{[XluIFfJOVAhRSB{LkGyOUDPxE1w	NVzmUW5VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwOFM4QTRpPkK4NFQ{Pzl2PD;hQi=>
BAF3	NGrwbYVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		Ml3pO\|IhcHK\|	NF;WToNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGZNXDNvSWTEMWQ5OzWJIH31eIF1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD6wNFA{KM7:TT6=	Mo\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	NILJSZpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NG\XOG04OiCqcoO=	M2\1TWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegSmxVOy2LVFStSFg{PUFibYX0ZZRqd25iYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkCwNFMh\|ryPLh?=	NHfKS\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVy3NkBpenN?	M1jDNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegSmxVOy2GOEO1TEBufXSjdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODByMzFOwG0v	NE\EcJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
MOLM13	M{XLU2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYXsXGRwPzJiaILz	NUO0XHQ1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE[OVEOtTXRFKG23dHH0bY9vKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOC5yMECzJO69VS5?	MonuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	NXHwUJJSSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NEj1TpU4OiCqcoO=	NG\4XllCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOg[ZhxemW\|c3nu[{BVTUxvZoXz[YQhTkyWMzDrbY5ie2ViYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkCwNFMh\|ryPLh?=	NGX5NFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MXu3NkBpenN?	NE\NPXJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGZNXDNvSWTEMWQ5OzWQIH31eIF1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD6wNFA{KM7:TT6=	NGnMelg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
MOLM14	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NUH4N4pkPzJiaILz	MXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xOEBk\WyuczDoZZJjd3KrbnegSmxVOy2LVFSgcZV1[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlAxODNizszNMi=>	NHT3N2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	M2XuRWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3HBVlczKGi{cx?=	NWXJWmZmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BHVFR\|LVnUSEBufXSjdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODByMzFOwG0v	M{nGb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MV4-11	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmHzO\|IhcHK\|	MnXsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlAxODNizszNMi=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	MlPlRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MnfBO\|IhcHK\|	MnjMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDUSWwu\nW\|ZXSgVGRITlKjbIDoZU11emGwc3\vdo1m\CCvb4Xz[UBDSUZ\|IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOC5yMECzJO69VS5?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	MnzIRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXzLPGZHPzJiaILz	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIF\MWFMuTDh\|NWmgcZV1[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlAxOiEQvF2u	MoDOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	NVr4b4JGSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVvxOJlJPzJiaILz	M3nTNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgWGVNNW[3c3XkJHBFT0[UYnX0ZU11emGwc3\vdo1m\CCvb4Xz[UBDSUZ\|IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOC5yMES0JO69VS5?	MmjEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	MkK1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NFGxdZA4OiCqcoO=	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIF\MWFMuTDh\|NW[gcZV1[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlAyOSEQvF2u	NVjSSIVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
BAF3	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NGrjRlE4OiCqcoO=	M2XlXmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegSmxVOy2LVFStSFg{PWSnbDDteZRifGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuNFEzKM7:TT6=	NXj0Z4ZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
Sf9	NEH5bnJHfW6ldHnvckBie3OjeR?=		M2LPOVEhcHJ?	MWDJcohq[mm2aX;uJI9nKGi3bXHuJG1XPC1zMTDj[Yxtey2mZYLpeoVlKEircz30ZYdo\WRiRlzUN{BKXERibYX0ZY51KCh3NkSgeI8hQTl\|IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRic3[5JINmdGy\|IIXzbY5oKHCxbImgLFQ7OSCJbIWsJHR6eiliYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliQVTQMWdtdyCtaX7hd4Uh[XO\|YYmsJGlEPTBiPTCwMlAyPjhizszNMi=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	MlLhRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXzXOWdFPzJiaILz	MmPJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDUSWwu\nW\|ZXSgZ2tKXC22cnHud4Zwem2nZDDtc5V{\SCEQV[zJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD6wNVch\|ryPLh?=	M3PKcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	NWKwb2R3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1;JNVczKGi{cx?=	NGXleldCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHRGVC2odYPl[EBEW0ZzUj30doFve2[xcn3l[EBud3W\|ZTDCRWY{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xOjRizszNMi=>	M4jkdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	Mn;ZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NEDmSZE4OiCqcoO=	NGrK[VJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGZNXDNvSWTEMWQ5OzW\IH31eIF1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD6wNlgh\|ryPLh?=	NHmy[5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
Sf9	MX3GeY5kfGmxbjDhd5NigQ>?		NWmwW\|A6OSCqch?=	NV7uRlBGUW6qaXLpeIlwdiCxZjDoeY1idiCKTE[wJINmdGy\|LXTldol3\WRiSHnzMZRi\2enZDDGUHQ{KCh3NkSgeI8hQTl\|IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRic3[5JINmdGy\|IIXzbY5oKHCxbImgLFQ7OSCJbIWsJHR6eiliYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliQVTQMWdtdyCtaX7hd4Uh[XO\|YYmsJGlEPTBiPTCwMlA{ODRizszNMi=>	NHK1[3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	MnjORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NX7GN3RKPzJiaILz	M3[5WGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegSmxVOy2LVFStSFg{PUlibYX0ZZRqd25iYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkC1OkDPxE1w	MofIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlnJO\|IhcHK\|	M17ldmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgWGVNNW[3c3XkJGRFWjJvdILhcpNnd3KvZXSgcY92e2ViQlHGN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuNVEh\|ryPLh?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	NVrw[mFRSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NYD6PW1LPzJiaILz	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGTFUE1nfXOnZDDESHIyNXS{YX7z[o9zdWWmIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkGyJO69VS5?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
CMK	MYLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NXjWXVRoPzJiaILz	NVzyXHpbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDUWsh[2WubIOg[ZhxemW\|c3nu[{BHVFR\|IHvpcoF{\SCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwMUKg{txONg>?	NIe3UmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	MUfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NFTMRpY4OiCqcoO=	MnW0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDUSWwu\nW\|ZXSgVmVVNXS{YX7z[o9zdWWmIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkGzJO69VS5?	NVfXN4hmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
HL60	M2q1cWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MX:3NkBpenN?	MonYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKTE[wJINmdGy\|IHX4dJJme3OrbnegSmxVOyCtaX7hd4Uh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjF\|IN88UU4>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	MnrORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3;wfFczKGi{cx?=	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGTFUE1nfXOnZDDGUHQ1NXS{YX7z[o9zdWWmIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkK3JO69VS5?	NVnYZ5piRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
BAF3	Ml3sRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYW3NkBpenN?	M3vmcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegSmxVOy2NNk[zVUBufXSjdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvOzdizszNMi=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NUTVTFBSPzJiaILz	MlTNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDUSWwu\nW\|ZXSgUGNMNXS{YX7z[o9zdWWmIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkSg{txONg>?	MoLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
U937	M3jYUWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVq3NkBpenN?	NX31XIVPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPVM4KGOnbHzzJIV5eHKnc4PpcochTkyWMzDrbY5ie2ViYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSBzLkKg{txONg>?	M4XHVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
SKM1	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M2LUNFczKGi{cx?=	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONTUGgZ4VtdHNiZYjwdoV{e2mwZzDGUHQ{KGurbnHz[UBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFEvOyEQvF2u	M{jLR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
NB4	M17lNWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MnvlO\|IhcHK\|	NGLweWdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7COEBk\WyuczDlfJBz\XO\|aX7nJGZNXDNia3nuZZNmKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hPy5\|IN88UU4>	M4rJeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MOLM13	MXfD[YxtKGO7Y3zlJIF{e2G7	MoT3NVAxKG6P	NGTaVHgyOiCqcoO=	NFT5Zo5E\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBOV0yPMUOgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFewM2cyKHCqYYPlJIF1KDFyMDDuUUBi\nSncjCxNkBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDiZZNm\C2IQVPTJIFv[Wy7c3nz	M3nuWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MOLM14	MUXD[YxtKGO7Y3zlJIF{e2G7	NGPMdlIyODBibl2=	MlX4NVIhcHK\|	M{mxOWNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJG1QVE1zNDDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS\|EheGijc3WgZZQhOTByIH7NJIFnfGW{IEGyJIhzeyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlNU[DQ2OgZY5idHm\|aYO=	NUfkfVE3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
MOLM13	M3rtZ2Fxd3C2b4Ppd{Bie3OjeR?=	M1HhflExOCCwTR?=	M{Phc\|EzKGi{cx?=	NYPTSoVsUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNU2xOOTNiY3XscJMh[XO\|ZYPz[YQh[XNiY3zlZZZi\2Vib3[gVGFTWCCjdDCxNFAhdk1iYX\0[ZIhOTJiaILzJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?=	MoPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
MV4-11	NIjzWYVCeG:ydH;zbZMh[XO\|YYm=	MoLBNVAxKG6P	M{TlVVQ5KGi{cx?=	NU\pPGZ[UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNWlQuOTFiY3XscJMh[XO\|ZYPz[YQh[XNiY3zlZZZi\2Vib3[gVGFTWCCjdDCxNFAhdk1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?=	M{LsR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MOLM13	MWPBdI9xfG:\|aYOgZZN{[Xl?	M4\zTVExOCCwTR?=	NEjrdFcyOiCqcoO=	NEDldGpKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF3PUG0yOyClZXzsd{Bie3Onc4Pl[EBieyClbHXheoFo\SCxZjDjZZNx[XOnLUOgZZQhOTByIH7NJIFnfGW{IEGyJIhzeyCkeTDpcY12dm:kbH;0eIlv\yCvZYToc4Q>	MknJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
MOLM14	MmrQRZBweHSxc3nzJIF{e2G7	MkLYNVAxKG6P	Mk\oNlQhcHK\|	NUPoZop1UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNU2xOOTRiY3XscJMh[XO\|ZYPz[YQh[XNiY3zlZZZi\2Vib3[gVGFTWCCjdDCxNFAhdk1iYX\0[ZIhOjRiaILzJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?=	NVvOU5MyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
MOLM14	NWfNR2psSXCxcITvd4l{KGG\|c3H5	NGrrNYcyODBibl2=	MUCyOEBpenN?	NF\V[lNKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF3PUG0yPCClZXzsd{Bie3Onc4Pl[EBieyClbHXheoFo\SCxZjDjZZNx[XOnLUOgZZQhOTByIH7NJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0eIlv\yCvZYToc4Q>	M2HBdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MV4-11	MkfGRZBweHSxc3nzJIF{e2G7	MUmxNFAhdk1?	M2fsXlQ5KGi{cx?=	NYPEeWtoUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNWlQuOTFiY3XscJMh[XO\|ZYPz[YQh[XNiY3zlZZZi\2Vib3[gZ4F{eGG\|ZT2zJIF1KDFyMDDuUUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmdibXX0bI9l	M{Lt[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MV4-11	NVHOWmFqS2WubDDjfYNt\SCjc4PhfS=>	M32zR\|ExOCCwTR?=	MkLLNVIhcHK\|	MUXD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDNWlQuOTFiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdyL1exJJBp[XOnIHH0JFExOCCwTTDh[pRmeiBzMjDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\yCkYYPl[E1HSUOVIHHuZYx6e2m\|	M{DnblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
Saos-2	NEL0[IJyUFSVIHHzd4F6			M1zw[pFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	Moj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	NYDpOXlWeUiWUzDhd5NigQ>?			NXP3O5JZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	MnHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	M3HjOZFJXFNiYYPzZZk>			M3vo[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTF{IHPlcIx{	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	M33rW5FJXFNiYYPzZZk>			NGK4fpRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>?	NIfE[WM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	NXroUGtMeUiWUzDhd5NigQ>?			NY\uNWV{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	NI\lWnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	MXnxTHRUKGG\|c3H5			NW\yZXo3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	NWizTWxMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	M4nEW5FJXFNiYYPzZZk>			M1:zfJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq	MnrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	MWnxTHRUKGG\|c3H5			NUXSSo94eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	NV;3O2ZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS	MkHGdWhVWyCjc4PhfS=>			MlfjdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWU0zKE:VIHPlcIx{	M{O1dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	MVPxTHRUKGG\|c3H5			MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDPTHMuPTBiY3XscJM>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	NV7N[HA2eUiWUzDhd5NigQ>?			MmLZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=>	NHjTPVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	Mn\LdWhVWyCjc4PhfS=>			M2L1Z5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	M13I[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NGnSUmtyUFSVIHHzd4F6			NY[4cG96eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NVv1RVRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	Ml7jdWhVWyCjc4PhfS=>			NWKybI5beUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	NYq1cFJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	MmXKdWhVWyCjc4PhfS=>			M3H3V5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DOTZ2MzDj[Yxtew>?	MoC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NYD0Xo15eUiWUzDhd5NigQ>?			NIKyNmhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy\|	MnjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	Mn;jdWhVWyCjc4PhfS=>			MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTTk1ISk1{IHPlcIx{	M4nr[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	NHjNeodyUFSVIHHzd4F6			M1TWOJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	M3\VXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MOLM13	NYDwOowxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnO3O\|IhcHK\|	MojQS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUW9NVTF\|IHPlcIx{KGGodHXyJFczKGi{czDifUBk[WylZXnuJGFOKGS7ZT3iZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFfJOVAhRSByLkCwNkDPxE1w	NGLJUo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[3NlA1QSd-Mkm2O\|IxPDl:L3G+
MV4-11	M{CxZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVjZOFlUPzJiaILz	MX;Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNWlQuOTFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JINidGOnaX6gRW0h\HmnLXLhd4VlKG[udX;y[ZNk\W6lZTDhd5NigSxiR1m1NEA:KDBwMECzJO69VS5?	NYHHO5BCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2O\|IxPDlpPkK5OlczODR7PD;hQi=>
BA/F3	MoPKSpVv[3Srb36gZZN{[Xl?		MlzvO\|IhcHK\|	Mlm4TY5pcWKrdHnvckBw\iCITGSzJGlVTCCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDtc5V{\SCEQT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgZ4Ft[2WrbjDBUUBlgWVvYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCJSUWwJF0hOC5yMEeg{txONg>?	MnfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4N{KwOFkoRjJ7NkeyNFQ6RC:jPh?=
Sf9	NX;WVVRSTnWwY4Tpc44h[XO\|YYm=			MlTrTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFfTWE9JcXN4LX\1d4VlKHKnY3;tZolv[W62IHj1cYFvKE[OVEOgLHI2PzFidH:gV\|k6OyC{ZYPp[JVmeyliSWTEJI12fGGwdDDlfJBz\XO\|ZXSgbY4hW2Z7IHnud4VkfCClZXzsd{B2e2mwZzDwc4x6KCiDbHGsS4x2NEy7czzUfZIqKDZ8Mkq1PlEhcHmmcn;ido9ucWSnIHHzJJN2[nO2cnH0[UBqdiCycnXz[Y5k\SCxZjDb[4FudWFvM{PQYWFVWCxiSVO1NEA:KDBwMEGg{txONg>?	NFOyeW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[3NlA1QSd-Mkm2O\|IxPDl:L3G+
Sf9	MnPaSpVv[3Srb36gZZN{[Xl?			MYnJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiR2PUM2hqezZvZoXz[YQhemWlb33ibY5idnRid3ns[EB1gXCnIHj1cYFvKE[OVEOgLHI2PzFidH:gV\|k6OyC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJHNnQSCrboPlZ5Qh[2WubIOgeZNqdmdicH;sfUApSWyjLFfseUxNgXNuVInyLUA3QjJ8NUqxJIh6\HKxYoLvcYll\SCjczDzeYJ{fHKjdHWgbY4heHKnc3XuZ4Uhd2ZiW3fhcY1iNTN\|UG3BWHAtKEmFNUCgQUAxNjB\|NjFOwG0v	NWPMW2tIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2O\|IxPDlpPkK5OlczODR7PD;hQi=>
Kasumi-1	NHm2cplIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3fH[VczKGi{cx?=	MlHkS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT4F{fW2rLUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOjbHPlbY4hSU1iZInlMYJie2WmIH\seY9z\XOlZX7j[UBie3OjeTygS2k2OCB;IECuNFY1KM7:TT6=	NIjUOIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[3NlA1QSd-Mkm2O\|IxPDl:L3G+
Sf9	M4fMdmZ2dmO2aX;uJIF{e2G7			MULJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiR2PUM2hqezZvZoXz[YQhemWlb33ibY5idnRiaIXtZY4hTkyWMzCoVlU4OSC2bzDTPVk{KHKnc3nkeYV{MSCGOEO1XUBufXSjboSg[ZhxemW\|c3XkJIlvKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegdI9tgSBqQXzhMGdtfSyOeYOsWJlzMSB4OkK6OVoyKGi7ZILvZpJwdWmmZTDhd{B{fWK\|dILheIUhcW5icILld4Vv[2Vib3[gX4didW2jLUOzVH1CXFBuIFnDOVAhRSByLkGzOkDPxE1w	NEPvSmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[3NlA1QSd-Mkm2O\|IxPDl:L3G+
BA/F3	NIjMc2pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2L5blczKGi{cx?=	MmnBS5Jwf3SqIHnubIljcXSrb36gc4YhdW:3c3WgRmEwTjNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JINidGOnaX6gRW0h\HmnLXLhd4VlKG[udX;y[ZNk\W6lZTDhd5NigSxiR1m1NEA:KDFwNEWyJO69VS5?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ5MkC0PUc,Ojl4N{KwOFk9N2F-
MV4-11	M3vIfmZ2dmO2aX;uJIF{e2G7	NFvxOXAxNjBzIITvJFExOCCwTR?=	NGXjfFYyKGi{	NFzPcJJKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCrbjDoeY1idiCPVkStNVEh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iQVvUJJBpd3OyaH;yfYxifGmxbjDheEBUPDd\|IHH0JFAvODFidH:gNVAxKG6PIHHmeIVzKDFiaIKgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>?	NVOzVppIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2O\|IxPDlpPkK5OlczODR7PD;hQi=>
MV4-11	M2rsZ2Z2dmO2aX;uJIF{e2G7	M13XVVAvODFidH:gNVAxKG6P	NX3aWHZpOSCqch?=	NIHmVJpKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCrbjDoeY1idiCPVkStNVEh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iTVXLNU8zKHCqb4PwbI9zgWyjdHnvckBifCCVMkG3M\|IzOSCjdDCwMlAyKHSxIEGwNEBvVSCjZoTldkAyKGi{IHL5JIludXWwb3Lsc5Qh[W6jbInzbZM>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ5MkC0PUc,Ojl4N{KwOFk9N2F-
MV4-11	MmjqSpVv[3Srb36gZZN{[Xl?	MYOxJI5O	NXz0XYxyOSCqch?=	MlTTTY5pcWKrdHnvckBw\iCITGSzJGlVTCCvdYThcpQh[XW2b4Doc5NxcG:{eXzheIlwdiCjdDDZOVg6NzV7MTDpckBpfW2jbjDNWlQuOTFiY3XscJMh[XRiMTDuUUBi\nSncjCxJIhzKGK7IHntcZVvd2Kub4SgZY5idHm\|aYO=	M4X6dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkeyNFQ6Lz5{OU[3NlA1QTxxYU6=
MV4-11	MYTGeY5kfGmxbjDhd5NigQ>?	MoezNUBvVQ>?	NYjFV\|VsOSCqch?=	M1Ls[mlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25iYYSgXVg1OiCrbjDoeY1idiCPVkStNVEh[2WubIOgZZQhOSCwTTDh[pRmeiBzIHjyJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN?	NYTneXpZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2O\|IxPDlpPkK5OlczODR7PD;hQi=>
MV4-11	NEmwVo9HfW6ldHnvckBie3OjeR?=	M4\Q[VAvODFidH:gNVAxKG6P	NHe0Xm4yKGi{	Mn7ZTY5pcWKrdHnvckBw\iCITGSzJGlVTCCvdYThcpQhcW5iaIXtZY4hVVZ2LUGxJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKFOWQWS1JJBpd3OyaH;yfYxifGmxbjDheEB[Pjl2IHH0JFAvODFidH:gNVAxKG6PIHHmeIVzKDFiaIKgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>?	NHjUbVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[3NlA1QSd-Mkm2O\|IxPDl:L3G+
MV4-11	NFTIOW1HfW6ldHnvckBie3OjeR?=	NXv4d3dMOC5yMTD0c{AyODBibl2=	M3yxRlEhcHJ?	MUDJcohq[mm2aX;uJI9nKE[OVEOgTXRFKG23dHHueEBqdiCqdX3hckBOXjRvMUGgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hTVKNMT:yJJBpd3OyaH;yfYxifGmxbjDheEBVOjB{L2myNFQh[XRiMD6wNUB1dyBzMECgcm0h[W[2ZYKgNUBpeiCkeTDpcY12dm:kbH;0JIFv[Wy7c3nz	NXTse2J2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2O\|IxPDlpPkK5OlczODR7PD;hQi=>
MV4-11	NGC4R\|lHfW6ldHnvckBie3OjeR?=	NEnhNoIyOCCvZz;r[y=>	Mk\RNlQhcHK\|	MVHJckB3cX[xIHnubIljcXSrb36gc4YhTkyWMzDJWGQhdXW2YX70JIlvKGi3bXHuJG1XPC1zMTDj[YxteyC6ZX7v[5Ji\nSnZDDpckBifGi7bXnjJI52N263IH3veZNmKGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJHNVSVR3IIDoc5NxcG:{eXzheIlwdiCjdDDZOlk1KGG2IEGwJI1oN2upLDDpdEBi\nSncjCyOEBpenNiYomgbY1ufW6xYnzveEBu\XSqb3SgdoVt[XSrdnWgeI8h[2:wdILvcC=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ5MkC0PUc,Ojl4N{KwOFk9N2F-
MV4-11	M2LGO2Z2dmO2aX;uJIF{e2G7	Mn7NNE4yKHWP	NW\iXZRSPCCqcoO=	MYXJcohq[mm2aX;uJI9nKE[OVEOgbY4hcHWvYX6gUXY1NTFzIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IGPldlQ4OyC{ZYPp[JVmKGG2IECuNUB2VSCjZoTldkA1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MlvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6OUS5OFQoRjJ7OEm0PVQ1RC:jPh?=
MV4-11	MXzGeY5kfGmxbjDhd5NigQ>?	NGDjWZQxNjFidV2=	MknUOEBpenN?	NYnzZ4c2UW6qaXLpeIlwdiCxZjDGUHQ{KGmwIHj1cYFvKE2YND2xNUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iU2TBWFUheGixc4Doc5J6dGG2aX;uJIF1KFS7ck[5OEBz\XOrZIXlJIF1KDBwMTD1UUBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NETtS2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi5OFk1PCd-Mkm4PVQ6PDR:L3G+
MV4-11	MVTGeY5kfGmxbjDhd5NigQ>?	MUmwMlEhfU1?	MkPaOEBpenN?	M4PPWmlvcGmkaYTpc44hd2ZiRlzUN{BqdiCqdX3hckBOXjRvMUGgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWUS{GvNkBxcG:\|cHjvdplt[XSrb36gZZQhXGi{MkCyM3R6ejJyNDDy[ZNq\HWnczDheEAxNjFidV2gZYZ1\XJiNDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NFTHXYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi5OFk1PCd-Mkm4PVQ6PDR:L3G+
MV4-11	MoLQSpVv[3Srb36gZZN{[Xl?	NWXKd2tpOC5zIIXN	MW[0JIhzew>?	NETCZppKdmirYnn0bY9vKG:oIF\MWFMheGixc4Doc5J6dGG2aX;uJIF1KFS7ckW4PU82QTFicnXzbYR2\XNiaX6gbJVu[W5iTW[0MVEyKGOnbHzzJIF1KDBwMTD1UUBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	M1rD[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEm0PVQ1Lz5{OUi5OFk1PDxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-FLT3 / FLT3; PubMed: 22875611 Haematologica (B) The same cells were also harvested for Western blot analysis after treatment for 90 min with different concentrations of AC220. The phosphorylation of the different FLT3 proteins was determined using a phospho-FLT3 antibody. p-STAT5 / STAT5 / β-catenin / p-AKT / AKT / p-ERK / ERK / p-S6 / S6; PubMed: 28625976 Cancer Res Western blot analysis of AC220 treated MV4-11 cells. Cells were starved for overnight and treated with AC220 at indicated concentrations. Cells were harvested after 2 hours treatment and lysed. Then western blots analysis was performed. The quantification of bands are shown below the gel.	22875611 28625976
Immunofluorescence	WGA / FLT3 ; PubMed: 28895560 Leukemia Immunofluorescence staining of FLT3-WT, FLT3 mutants or empty vector with or without AC220 treatment in transiently transfected U2OS cells. WGA (wheat germ agglutinin). Scale bar: 25 μm.	28895560
Growth inhibition assay	Cell viability; PubMed: 23967177 PLoS One K562/ABCB1 and K562/ABCG2 cells exhibit collateral sensitivity toquizartinib. K562, K562/ABCB1 and K562/ABCG2 cells were plated in the presence of quizartinib in increasing concentrations for 96 hours and viable cells were measured using the WST-1 assay.	23967177

In vivo

Oral administration of AC220 (10 mg/kg) induces time-dependent inhibition of FLT3 autophosphorylation in the FLT3-ITD–dependent MV4-11 tumor xenograft mouse model; the inhibition being 90% at 2 hours and 40% at 24 hours. AC220 significantly extends survival in a mouse model of FLT3-ITD AML with doses as low as 1 mg/kg given orally once a day. Treatment with AC220 at 10 mg/kg for 28 days results in rapid and complete regression of tumors in all mice with no tumor regrowth during the 60-day posttreatment period. AC220 displays more significant efficacy compared to sunitinib treatment which causes tumors to shrink slowly and resume growth immediately upon discontinuation of treatment in all but one of the mice. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Inhibition of FLT3 autophosphorylation: To measure inhibition of FLT3 autophosphorylation, MV4-11 or RS4;11 cells are cultured in low serum media (0.5% FBS) overnight and seeded at a density of 400 000 cells per well in a 96-well plate the following day. The cells are incubated with different concentrations of AC220 for 2 hours at 37 °C. To induce FLT3 autophosphorylation in RS4;11 cells, 100 ng/mL FLT3 ligand is added for 15 minutes after the 2-hour AC220 incubation. Cell lysates are prepared and incubated in 96-well plates precoated with a total FLT3 capture antibody. The coated plates are incubated with either a biotinylated antibody against FLT3 to detect total FLT3 or an antibody against phosphotyrosines to detect FLT3 autophosphorylation. In both cases, a SULFO-tagged streptavidin secondary antibody is used for electrochemiluminescence detection on the Meso Scale Discovery platform. The concentration of AC220 that inhibits FLT3-ITD or TLT3-WT autophosphorylation by 50% represents IC50 value
Cell Research:^[1]	- Collapse Cell lines: MV4-11 and RS4;11 cells Concentrations: Dissolved in DMSO, final concentration ~20 μM Incubation Time: 72 hours Method: Cells are cultured overnight in low serum media (0.5% FBS), seeded in a 96-well plate at 40 000 cells per well and exposed to AC220 for 72 hours at 37 °C. Cell viability is measured using the Cell Titer-Blue Cell Viability Assa (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female NU/NU or severe combined immunodeficient mice implanted with MV4-11 cells Dosages: ~10 mg/kg Administration: Oral gavage (Only for Reference)

References

[1] Zarrinkar PP, et al. Blood, 2009, 114(14), 2984-2992.

Solubility (25°C)

In vitro	DMSO	33 mg/mL (58.85 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 15% Captisol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Quizartinib (AC220) SDF

Molecular Weight	560.67
Formula	C₂₉H₃₂N₆O₄S
CAS No.	950769-58-1
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04459598	Completed	Drug: Efavirenz\|Drug: Quizartinib	Healthy Subjects\|Drug-drug Interaction\|Pharmacokinetics\|Quizartinib	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	September 8 2020	Early Phase 1
NCT04473664	Completed	Drug: Quizartinib	Hepatic Impairment\|Moderate Impaired Hepatic Function	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	September 29 2020	Phase 1
NCT04459585	Completed	Drug: Dabigatran Etexilate Mesylate\|Drug: Quizartinib	Healthy Subjects\|Drug-drug Interaction\|Pharmacokinetics\|Quizartinib	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	August 28 2020	Early Phase 1
NCT04209725	Terminated	Drug: CPX-351\|Drug: Quizartinib	Leukemia Myeloid Acute	SCRI Development Innovations LLC	June 3 2020	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is it possible to alter the captisol concentration to make it more dissolvable i.e 20% or 25% captisol ?
Answer:
In 15% Captisol, the compound forms s suspension at 30mg/ml. Increasing the percentage of Captisol will not convert the mixture into solution. You can use suspension for oral gavage feeding.

Target Protein Ligand Inhibitors with Unique Features

FLT3 Inhibitor in Clinical Trial

Dovitinib (TKI-258, CHIR-258) : Phase III for Metastatic Renal Cell Carcinoma.

Choose Your Country or Region

By Signaling Pathways

By product type

Quizartinib (AC220)